The ability of HDAC11 inhibition to function in a β-AR–independent manner to bypass AT catecholamine resistance underscores the potential of targeting this lysine demyristoylase as a therapeutic strategy for metabolic diseases that have been recalcitrant to β3-AR agonists. Here, ADRB2 is linked to Other metabolic disease.